机构

• 上海药物研究所 [10]
• 合肥物质科学研究院 [2]
• 上海应用物理研究所 [1]

采集方式

• OAI收割 [13]

内容类型

• 期刊论文 [13]

发表日期

• 2024 [1]
• 2023 [1]
• 2022 [1]
• 2021 [1]
• 2020 [3]
• 2019 [1]
• 更多

学科主题

筛选

浏览/检索结果: 共13条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors 期刊论文  OAI收割 JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 卷号: 17, 期号: 1, 页码: 32 作者:  Wei, Qing;  Li, Peijing;  Yang, Teng;  Zhu, Jiayu;  Sun, Lu   |  收藏  |  浏览/下载：24/0  |  提交时间：2024/02/27 Antibody-drug conjugate  Solid tumor  Combination therapy  Immunotherapy  Targeted therapy   Conjugation site characterization of antibody-drug conjugates using electron-transfer/higher-energy collision dissociation (EThcD) 期刊论文  OAI收割 ANALYTICA CHIMICA ACTA, 2023, 卷号: 1251, 页码: 7 作者:  Song, Yuanli;  Gao, Jing;  Meng, Qian;  Tang, Feng;  Wang, Yuqiu   |  收藏  |  浏览/下载：21/0  |  提交时间：2023/10/17 Antibody -drug conjugates  EThcD  Conjugation site  Peptide mapping  Quality control   CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2022 作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang   |  收藏  |  浏览/下载：53/0  |  提交时间：2022/03/28 HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance   Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer 期刊论文  OAI收割 FRONTIERS IN PHARMACOLOGY, 2021, 卷号: 12 作者:  Yang, ZiYan;  Wang, Wei;  Wang, Xiaojia;  Qin, ZhiQuan   |  收藏  |  浏览/下载：46/0  |  提交时间：2022/01/10 cardiotoxicity  ErbB2  targeting drugs  breast cancer  therapy   An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer 期刊论文  OAI收割 CANCER MEDICINE, 2020, 页码: 12 作者:  Pan, Deng;  Tang, Yubo;  Tong, Jiao;  Xie, Chengmei;  Chen, Jiaxi   |  收藏  |  浏览/下载：33/0  |  提交时间：2020/12/24 YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer 期刊论文  OAI收割 BRITISH JOURNAL OF CANCER, 2020, 页码: 12 作者:  Wang, Lei;  Wang, Quanren;  Xu, Piaopiao;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：18/0  |  提交时间：2020/12/24 DNA Origami-Enabled Engineering of Ligand-Drug Conjugates for Targeted Drug Delivery 期刊论文  OAI收割 SMALL, 2020, 卷号: 16, 期号: 16, 页码: - 作者:  Ge, ZL;  Guo, LJ;  Wu, GQ;  Li, J;  Sun, YL   |  收藏  |  浏览/下载：31/0  |  提交时间：2021/09/06 TRASTUZUMAB EMTANSINE  BRENTUXIMAB VEDOTIN  CANCER-THERAPY  ANTIBODY  NANOSTRUCTURES  NANOROBOT  TRANSPORT  EFFICACY  IMPROVES  SYSTEM   Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial 期刊论文  OAI收割 CLINICAL CANCER RESEARCH, 2019, 卷号: 25, 期号: 17, 页码: 5212-5220 作者:  Li, Qiao;  Guan, Xiuwen;  Chen, Shanshan;  Yi, Zongbi;  Lan, Bo   |  收藏  |  浏览/下载：26/0  |  提交时间：2020/07/01 STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer 期刊论文  OAI收割 CANCER SCIENCE, 2018, 卷号: 109, 期号: 10, 页码: 3305-3315 作者:  Wang, Lei;  Wang, Quanren;  Gao, Mingzhao;  Fu, Li;  Li, Yun   |  收藏  |  浏览/下载：50/0  |  提交时间：2019/01/08 drug resistance  leukemia inhibitory factor receptor  secreted factor  STAT3  trastuzumab-emtansine   Current Strategies and Applications for Precision Drug Design 期刊论文  OAI收割 FRONTIERS IN PHARMACOLOGY, 2018, 卷号: 9 作者:  Wang, Chen;  Xu, Pan;  Zhang, Luyu;  Huang, Jing;  Zhu, Kongkai   |  收藏  |  浏览/下载：47/0  |  提交时间：2019/01/08 precision medicine  precision drug design  computational modeling  deep learning  antibody-drug conjugates  ligand-targeted conjugates